Ovarian cancer trials in France

In France 99 Also abroad 795

99 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Where
Lyon, Nice Cedex 2, Rennes Cedex, Saint-Herblain Cedex, Strasbourg Cedex 2, Villejuif
Age
18 years and over
People
156 worldwide
Run by
Context Therapeutics Inc.
See details and how to joinNCT06515613 · EU 2025-523968-20-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Where
Avignon, Bordeaux, Caen Cedex 5, Chambray-lès-Tours, Lille, Paris, Pierre-Bénite, Plérin, Saint-Herblain Cedex, Toulouse, Villejuif
Age
18 years and over
People
770 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00
Phase 3Taking people
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Where
Angers, Brest, Clermont-Ferrand, Lille, Limoges, Lyon, Marseille, Montpellier Cedex 5, Plérin, Strasbourg Cedex 2, Toulouse, Tours, Villejuif
Age
18 years and over
People
900 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00
Phase 1Not yet taking people in France
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
Where
Lyon, Saint-Herblain, Toulouse, Villejuif
Age
18 years and over
People
370 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07928258 · EU 2026-526553-33-00
Phase 1Taking people
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Where
Besancon Cedex, Bordeaux, Dijon, Paris, Pierre Benite Cedex, Rennes Cedex, Saint-Herblain, Strasbourg Cedex 2, Toulouse Cedex 9, Villejuif Cedex
Age
18 years and over
People
172 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT04516447 · EU 2025-524868-38-00
Phase 3Taking people
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Where
Besançon, Brest, Dijon, Lyon, Marseille, Paris, Pierre-Bénite, Saint-Herblain, Strasbourg, Villejuif
Age
18 years and over
People
420 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500
No phaseTaking people
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
Where
Montpellier
Age
18 years and over
People
120
Run by
Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT06084195
Phase 3Taking people
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Where
Brest, Dijon, Lyon, Marseille, Paris, Saint-Priest-en-Jarez, Toulouse
Age
18 years and over
People
950 worldwide
Run by
AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Lyon, Saint-Herblain Cedex, Toulouse Cedex 9
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Villejuif
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Bordeaux, Brest, Lille, Montpellier, Pierre-Bénite, Villejuif
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 3Taking people
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Where
Angers, Bayonne, Besançon, Bordeaux, Brest, Lille, Limoges, Lyon Cedex08, Montpellier, Paris, Strasbourg
Age
18 years and over
People
1,630 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
Where
Bordeaux, Caen Cedex 5, Chambray-lès-Tours, Clermont Ferrand Cedex1, Nimes Cedex 9, Paris, Pierre-Bénite, Plerin, Reims, Saint-Priest-en-Jarez
Age
18 years and over
People
688 worldwide
Run by
Genmab
See details and how to joinNCT07564141 · EU 2025-524202-15-00
Phase 3Taking people
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Where
Besancon Cedex, Dijon, Lille, Lyon, Montpellier Cedex 5, Paris
Age
18 years and over
People
270 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00
Phase 3Taking people
Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression
Where
Besançon, Brest, Dijon, Lyon, PARIS, Pierre-Bénite, Saint-Herblain Cedex, Strasbourg, Villejuif
Age
18 years and over
People
197 worldwide
Run by
K-Group Beta Inc.
See details and how to join2025-524641-27-00 · EU 2025-524641-27-00
Phase 2Taking people
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Where
Besancon Cedex, Brest, Dijon, Lille, Lyon, Nice Cedex 2, Paris, Pierre-Bénite, St Herblain, Strasbourg, Strasbourg Cedex 2, Toulouse, Villejuif
Age
18 years and over
People
310 worldwide
Run by
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT05128825 · EU 2022-502983-19-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Angers, Dijon, Lyon, Marseille, Paris, Poitiers, Saint-Herblain Cedex
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Where
Bordeaux, Dijon, Lille Cedex, Lyon, Montpellier Cedex 5, Nantes Cedex 2, Paris, Paris Cedex 15, Rennes Cedex, Saint-Priest-en-Jarez
Age
18 years and over
People
582 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00
Phase 2/3Taking people
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Where
Bordeaux, Caen Cedex 5, Clermont Ferrand Cedex1, Dijon, Lyon, Marseille, Montpellier Cedex 5, Nantes Cedex 2, Paris, Plérin, Saint-Cloud, Vandoeuvre Les Nancy_ Cedex
Age
18 years and over
People
860 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy, Villejuif
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Besancon Cedex, Bordeaux, Bordeaux Cedex, Dijon, Lyon, Montpellier Cedex 5, Paris, Rennes Cedex, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1/2Taking people
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Where
Bordeau, Marseille, Paris, Poitiers, Villejuif
Age
18 years and over
People
542 worldwide
Run by
Artios Pharma Ltd
See details and how to joinNCT04657068
Phase 3Taking people
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Where
Bordeaux, Chambray-lès-Tours, Grenoble Cedex 9, La Roche Sur Yon Cedex 9, Lyon, Marseille, Rennes Cedex, Strasbourg Cedex 2, Villejuif
Age
18 years and over
People
466 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07214779 · EU 2025-522748-42-00
No phaseTaking people
Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation
Where
Marseille
Age
18 years and over
People
5,000
Run by
Institut Paoli-Calmettes
See details and how to joinNCT03667417
Phase 2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Where
Avignon Cedex 9, Bordeaux, Caen Cedex 5, Dijon, Limoges, Lyon, Nice Cedex 2, Plérin, Reims, Saint-Cloud, Strasbourg, Toulouse, Villejuif
Age
18 years and over
People
400 worldwide
Run by
AbbVie
See details and how to joinNCT07059845 · EU 2025-521606-18-00